Articles
Workplace attrition threatens operational continuity and clinical trial timelines for life science professionals. The recent shift to remote and decentralized trials presents unique challenges. Fuelled by systemic issues like burnout and depersonalization, and the unique pressures of data-intensive remote work, traditional retention strategies are failing.
AI-augmented managed service providers (MSPs) offer a predictive alternative that transforms retention into proactive strategies. Modern health care professionals use deep learning to find hidden patterns and analyze workloads. By scheduling against real-world volatility, they can identify attrition risk and incorporate targeted interventions. Ultimately, they create a more resilient workforce. Organizations must vet, implement and measure the ROI of these strategic partnerships.
...
Safety data overload in pharmacovigilance occurs when drug-safety teams receive extremely large volumes of safety information—such as ICSRs, literature reports, EHR data, and social-media inputs—making it difficult to quickly identify genuine safety signals. Excessive and often low-quality data, including duplicates and inconsistencies, can create noise, increase analyst workload, and delay critical risk-management decisions.
This challenge affects signal detection and assessment by causing false positives, alert fatigue, and slower regulatory responses. To address it, organizations are increasingly adopting AI-driven analytics, data standardization, automated deduplication, and advanced signal-detection tools to prioritize meaningful safety insights and ensure efficient pharmacovigilance operations.
Digital Pharmaceutical Supply Chain Management Market Set to Grow at 9% CAGR Amid Rising Demand for Transparency and Drug Traceability
Market Overview The digital pharmaceutical supply chain management market is projected to expand at a compound annual growth rate (CAGR) of approximately 9% between 2025 and 2030, reflecting the growing transition toward technology-driven supply chain ecosystems in the pharmaceutical industry. As pharmaceutical supply networks become more complex and globalized, organizations are increasingly adopting digital technologies to improve visibility, efficiency, and operational resilience. Pharmaceutical companies face mounting pressure to maintain product integrity, ensure regulatory compliance, and quickly respond to fluctuating market demands. Digital supply ch…
Market Overview The digital pharmaceutical supply chain management market is projected to expand at a compound annual growth rate (CAGR) of approximately 9% between 2025 and 2030, reflecting the growing transition toward technology-driven supply chain ecosystems in the pharmaceutical industry. As pharmaceutical supply networks become more complex and globalized, organizations are increasingly adopting digital technologies to improve visibility, efficiency, and operational resilience. Pharmaceutical companies face mounting pressure to maintain product integrity, ensure regulatory compliance, and quickly respond to fluctuating market demands. Digital supply ch…
Joint Clinical Assessment JCA is a new EU level clinical evaluation process under Regulation 2021 2282. Mandatory from January 2025 for oncology and advanced therapies, it harmonises comparative clinical assessments across member states. Running in parallel with EMA review, JCA reshapes evidence strategy, trial design, and market access planning across pharma and biotech.
The introduction of Joint Clinical Assessment JCA marks one of the most significant regulatory and market access changes in the European pharmaceutical landscape in decades. Established under the European Health Technology Assessment Regulation Regulation 2021 2282, JCA is reshaping how clinical evidence is assessed across EU member states. For professionals working in regulatory affairs, market access, HEOR, clinical dev…
The introduction of Joint Clinical Assessment JCA marks one of the most significant regulatory and market access changes in the European pharmaceutical landscape in decades. Established under the European Health Technology Assessment Regulation Regulation 2021 2282, JCA is reshaping how clinical evidence is assessed across EU member states. For professionals working in regulatory affairs, market access, HEOR, clinical dev…
Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales Organisations (CSOs) - reflects broader expansion across the UK and European pharmaceutical outsourcing market.
Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales O…
Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales O…
Alkermes is a fully integrated biopharmaceutical company headquartered in Dublin, Ireland, with R&D and manufacturing facilities in the U.S. With $1.5B in annual revenue, Alkermes has focused for more than 30 years on developing innovative treatments for psychiatric and neurological disorders. At a time when 40% of procurement teams said manual and inefficient processes are holding them back[1], the company turned to JAGGAER to improve spend visibility and create standardized workflows across departments and sites. The result has increased usability and brought a 23% reduction in purchase order (PO) processing costs and a 32% reduction in cycle times.
Alkermes is a fully integrated biopharmaceutical company headquartered in Dublin, Ireland, with R&D and manufacturing facilities in the…
Alkermes is a fully integrated biopharmaceutical company headquartered in Dublin, Ireland, with R&D and manufacturing facilities in the…
From Passive Endpoints to Engineered Outcomes: The Clinical Case for Resilience in Oncology - By Nicolas Wolikow, Founder & CEO, Cure51
The integration of artificial intelligence and advanced computational modeling has already catalyzed a structural shift in global healthcare. In oncology, this "Precision Medicine" era has successfully moved the needle on early diagnostics and molecularly targeted therapies. However, while we have become experts at targeting the tumor, we are only just beginning to understand the host’s capacity for survival. The next evolution in cancer care will not be defined solely by the discovery of new molecules, but by the systematic deconstruction of survival itself. To truly advance, the industry must transition from viewing survival as a passive statistical endpo…
The integration of artificial intelligence and advanced computational modeling has already catalyzed a structural shift in global healthcare. In oncology, this "Precision Medicine" era has successfully moved the needle on early diagnostics and molecularly targeted therapies. However, while we have become experts at targeting the tumor, we are only just beginning to understand the host’s capacity for survival. The next evolution in cancer care will not be defined solely by the discovery of new molecules, but by the systematic deconstruction of survival itself. To truly advance, the industry must transition from viewing survival as a passive statistical endpo…
Clinical data review and analysis ensures accuracy, compliance, and actionable insights in clinical trials. By combining rigorous data validation with advanced analytics, pharma teams can enhance trial integrity, support regulatory approval, and accelerate drug development timelines.
Clinical data review and analysis is a cornerstone of modern pharmaceutical research and development. With the growing complexity of clinical trials and regulatory requirements, accurate and efficient data management has never been more critical. Understanding the process from raw data collection to final analysis ensures that clinical findings are reliable, actionable, and compliant with global standards. At its core, clinical data review involves the systematic examination of trial data for accuracy, complete…
Clinical data review and analysis is a cornerstone of modern pharmaceutical research and development. With the growing complexity of clinical trials and regulatory requirements, accurate and efficient data management has never been more critical. Understanding the process from raw data collection to final analysis ensures that clinical findings are reliable, actionable, and compliant with global standards. At its core, clinical data review involves the systematic examination of trial data for accuracy, complete…
Learn how clinical trial supply management works, including forecasting, logistics, inventory control, and risk mitigation to ensure uninterrupted trials.
Clinical trial supply management is the backbone of successful clinical research, ensuring that investigational products reach study sites on time, in optimal condition, and in compliance with global regulations. Effective clinical trial supply chain management ensures trials run smoothly, safeguards patient safety, and preserves the integrity of clinical data. Modern clinical trials, including decentralized designs, global studies, and personalized therapies, demand a deep understanding of clinical supply operations. Leveraging advanced technology and AI-driven tools is essential to maintain operational efficiency, regulatory complia…
Clinical trial supply management is the backbone of successful clinical research, ensuring that investigational products reach study sites on time, in optimal condition, and in compliance with global regulations. Effective clinical trial supply chain management ensures trials run smoothly, safeguards patient safety, and preserves the integrity of clinical data. Modern clinical trials, including decentralized designs, global studies, and personalized therapies, demand a deep understanding of clinical supply operations. Leveraging advanced technology and AI-driven tools is essential to maintain operational efficiency, regulatory complia…
The audits are the main regulatory tool for many industries especially the medical device and pharmaceutical sector. The audits, whether they are internal, vendor-based, or regulatory, should be done by organizations to show that they comply with the strict quality standards of cGMP, QMS, and CAPA. The article exposes the ins and outs of audits, regulatory inspections, and compliance requirements, with a special emphasis on FDA inspections and the QSIT (Quality System Inspection Technique) approach.
Introduction to Audits In the fields of pharmaceuticals and medical devices where regulation is imposed, compliance with the quality standards set by the authorities is vital for the protection of the products from dangerous effects and ensuring therapeutic efficiency. Audits form an integral pa…
Introduction to Audits In the fields of pharmaceuticals and medical devices where regulation is imposed, compliance with the quality standards set by the authorities is vital for the protection of the products from dangerous effects and ensuring therapeutic efficiency. Audits form an integral pa…
In an industry where every healthcare provider (HCP) interaction carries significant weight, ACTO’s CxZone has been recognized for its approach to pharmaceutical field training. In the 2025 Pharmaceutical Technology Excellence Awards, ACTO won awards in both the Innovation (AI Roleplay) and Product Launches (Field Simulation) categories for CxZone.
ACTO’s approach to bridging the gap between strategy and execution, along with its integration into pharma field professionals’ workflows, has drawn attention within the life sciences sector.
ACTO’s CxZone won the Innovation award in the AI Roleplay category for its targeted use of AI roleplay to address persistent challenges in pharmaceutical field engagement. One of the most significant hurdles for pharmaceutical companies is ensuring that t…
ACTO’s CxZone won the Innovation award in the AI Roleplay category for its targeted use of AI roleplay to address persistent challenges in pharmaceutical field engagement. One of the most significant hurdles for pharmaceutical companies is ensuring that t…
The biggest recruitment fraud risks in 2026 are primarily driven by the democratisation and sophistication of Generative AI, which has transformed traditional "resume embellishment" into a systemic crisis of identity and qualification verification,.
The biggest recruitment fraud risks in 2026 are primarily driven by the democratisation and sophistication of Generative AI, which has transformed traditional "resume embellishment" into a systemic crisis of identity and qualification verification,. The following are the primary recruitment fraud risks identified for 2026: 1. AI-Powered Identity Deception (Deepfakes and Voice Cloning) One of the most concerning trends is the rise of real-time deepfake video and audio during virtual interviews,. Deepfake Avatars: Candidates use AI to overlay sto…
The biggest recruitment fraud risks in 2026 are primarily driven by the democratisation and sophistication of Generative AI, which has transformed traditional "resume embellishment" into a systemic crisis of identity and qualification verification,. The following are the primary recruitment fraud risks identified for 2026: 1. AI-Powered Identity Deception (Deepfakes and Voice Cloning) One of the most concerning trends is the rise of real-time deepfake video and audio during virtual interviews,. Deepfake Avatars: Candidates use AI to overlay sto…
06-Feb-2026
“An ounce of prevention is worth a pound of cure.” Benjamin Franklin’s maxim may predate modern medicine, yet its logic underpins the realities of pharmaceutical manufacturing today. When a single interruption can destabilise controlled systems, jeopardise batch integrity or delay time-critical medicines, preventing disruption is as important as resolving it. Here, Andrew Keith, division director of load bank manufacturer Power Prove, examines how robust backup power testing helps reduce unplanned downtime in pharmaceutical operations.
~ How load bank testing prevents downtime in pharmaceutical manufacturing ~ “An ounce of prevention is worth a pound of cure.” Benjamin Franklin’s maxim may predate modern medicine, yet its logic underpins the realities of pharmaceutical manufacturing today.…
~ How load bank testing prevents downtime in pharmaceutical manufacturing ~ “An ounce of prevention is worth a pound of cure.” Benjamin Franklin’s maxim may predate modern medicine, yet its logic underpins the realities of pharmaceutical manufacturing today.…
Pharmacovigilance (PV) teams are facing sustained pressure from rising ICSR volumes, expanding intake channels (partners, call centres, patient programs, digital touchpoints), tighter regulatory timelines, and higher expectations for inspection readiness. Many organisations, however, still run PV operations through fragmented mailboxes, manual triage queues, and spreadsheet-heavy reconciliation. The most effective modernisation approach is not “adding AI everywhere,” but redesigning PV workflows so repeatable work is orchestrated consistently, exceptions are handled early, and medical judgement remains explicit and auditable.
Modernizing Pharmacovigilance Operations: Practical Automation Patterns for Case Intake, Triage, and Signal Workflows Pharmacovigilance (PV) teams are facing a sustain…
Modernizing Pharmacovigilance Operations: Practical Automation Patterns for Case Intake, Triage, and Signal Workflows Pharmacovigilance (PV) teams are facing a sustain…
Explore how AI is transforming clinical trials—from study design and data management to monitoring, compliance, and faster trial outcomes
AI in clinical trials is addressing the challenges of escalating data complexity and accelerated timelines. AI in clinical trials is being used to handle increasing complexity, larger volumes of data, and shorter development timelines. It enhances not only operational efficiency but also the underlying approach to study design and management, facilitating faster and more reliable insights for strategic decisions. Introduction: Clinical Research at an Inflection Point Clinical trials remain the definitive mechanism for validating the safety, efficacy, and real-world applicability of new therapies and medical devices. Yet despite decades of methodological r…
AI in clinical trials is addressing the challenges of escalating data complexity and accelerated timelines. AI in clinical trials is being used to handle increasing complexity, larger volumes of data, and shorter development timelines. It enhances not only operational efficiency but also the underlying approach to study design and management, facilitating faster and more reliable insights for strategic decisions. Introduction: Clinical Research at an Inflection Point Clinical trials remain the definitive mechanism for validating the safety, efficacy, and real-world applicability of new therapies and medical devices. Yet despite decades of methodological r…
The global biomarkers market is at the forefront of healthcare’s shift toward precision, data-driven medicine. Valued at USD 85.9 billion in 2025 and projected to reach USD 244.8 billion by 2034 at a CAGR of 12.3%.
The landscape of modern healthcare is undergoing a seismic shift, moving away from "one-size-fits-all" treatments toward a highly tailored, data-driven approach. At the heart of this transformation is the global biomarkers market. Valued at USD 85.9 billion in 2025, the sector is projected to surge to an astonishing USD 244.8 billion by 2034. This trajectory, representing a compound annual growth rate (CAGR) of 12.3%, underscores a fundamental change in how we diagnose, monitor, and treat chronic diseases. The Catalysts of Growth: Why Now? The explosive expansion of the biomarker…
The landscape of modern healthcare is undergoing a seismic shift, moving away from "one-size-fits-all" treatments toward a highly tailored, data-driven approach. At the heart of this transformation is the global biomarkers market. Valued at USD 85.9 billion in 2025, the sector is projected to surge to an astonishing USD 244.8 billion by 2034. This trajectory, representing a compound annual growth rate (CAGR) of 12.3%, underscores a fundamental change in how we diagnose, monitor, and treat chronic diseases. The Catalysts of Growth: Why Now? The explosive expansion of the biomarker…
The use of AI in pharmaceutical development is becoming widespread, but the rulebook is still being written.
The use of AI in pharmaceutical development is becoming widespread, but the rulebook is still being written. McKinsey reports that 71% of businesses across various industries now use generative AI, with life sciences sitting among the fastest adopters. However, only 53% actively mitigate AI risks. This gap now leads to unease, as pharmaceutical companies deploy autonomous systems across R&D and manufacturing while simultaneously building their governance frameworks. The conversation has moved on from whether AI belongs in drug discovery or production lines. The big question is how those businesses secure innovation without restricting the impact that makes AI so valuable. Operati…
The use of AI in pharmaceutical development is becoming widespread, but the rulebook is still being written. McKinsey reports that 71% of businesses across various industries now use generative AI, with life sciences sitting among the fastest adopters. However, only 53% actively mitigate AI risks. This gap now leads to unease, as pharmaceutical companies deploy autonomous systems across R&D and manufacturing while simultaneously building their governance frameworks. The conversation has moved on from whether AI belongs in drug discovery or production lines. The big question is how those businesses secure innovation without restricting the impact that makes AI so valuable. Operati…
A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. The biological processes leave measurable traces in the blood, but only for a limited period. The discovery thus reveals a window of opportunity that could be crucial for future treatment, but also for early diagnosis via blood tests, which could begin to be tested in healthcare within five years.
Parkinson’s is an endemic disease with over 10 million people affected globally. As the world’s population grows older, this number is expected to more than double by 2050. At present, there is neither an effective cure nor an established screening method for detecting this chronic neurological d…
Parkinson’s is an endemic disease with over 10 million people affected globally. As the world’s population grows older, this number is expected to more than double by 2050. At present, there is neither an effective cure nor an established screening method for detecting this chronic neurological d…
24-Jan-2026
Explore the top EDC platforms for clinical trials in 2026. Features, strengths, limitations, and how to choose the right platform for your study.
Choosing the right EDC (electronic data capture) platform is critical for sponsors, CROs, and clinical operations teams running modern trials. In 2026, clinical trial software solutions have become increasingly sophisticated, ranging from enterprise suites to lean, budget-friendly tools. These clinical trial data capture software systems replace legacy tools with secure, centralized, and modern systems, ensuring 21 CFR Part 11 audit trails, encryption, and compliance with ICH-GCP guidelines. EDC systems are central to modern clinical trials, enhancing data accuracy while enabling real-time monitoring, faster database locks, and streamlined wor…
Choosing the right EDC (electronic data capture) platform is critical for sponsors, CROs, and clinical operations teams running modern trials. In 2026, clinical trial software solutions have become increasingly sophisticated, ranging from enterprise suites to lean, budget-friendly tools. These clinical trial data capture software systems replace legacy tools with secure, centralized, and modern systems, ensuring 21 CFR Part 11 audit trails, encryption, and compliance with ICH-GCP guidelines. EDC systems are central to modern clinical trials, enhancing data accuracy while enabling real-time monitoring, faster database locks, and streamlined wor…
Discover the predicted 2026 global rankings of China's leading pharmaceutical exporters, from innovation giants like Jiangsu Hengrui to emerging players. Explore trends, deals, and forecasts shaping the $177B export market.
In 2026, China's pharmaceutical export sector is poised for significant expansion, building on 2025's record-breaking out-licensing deals and a surge in innovative therapies. As the world's second-largest developer of new medicines, China is transitioning from a generics powerhouse to a global innovation leader, with exports projected to hit $176.92 billion—a substantial rise from $126.39 billion in 2024. This article, prepared for publication on www.pharmiweb.com, draws on authoritative sources like Statista, IQVIA, and the Pharma 50 rankings to forecast the latest glob…
In 2026, China's pharmaceutical export sector is poised for significant expansion, building on 2025's record-breaking out-licensing deals and a surge in innovative therapies. As the world's second-largest developer of new medicines, China is transitioning from a generics powerhouse to a global innovation leader, with exports projected to hit $176.92 billion—a substantial rise from $126.39 billion in 2024. This article, prepared for publication on www.pharmiweb.com, draws on authoritative sources like Statista, IQVIA, and the Pharma 50 rankings to forecast the latest glob…
